These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

918 related items for PubMed ID: 10193691

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 3. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [Abstract] [Full Text] [Related]

  • 4. Troglitazone.
    Spencer CM, Markham A.
    Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [Abstract] [Full Text] [Related]

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Jul; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 6. Troglitazone in type II diabetes mellitus.
    Sparano N, Seaton TL.
    Pharmacotherapy; 1998 Jul; 18(3):539-48. PubMed ID: 9620105
    [Abstract] [Full Text] [Related]

  • 7. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD, Campbell LK, Campbell RK.
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [Abstract] [Full Text] [Related]

  • 8. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.
    Ann Intern Med; 1998 Feb 01; 128(3):176-85. PubMed ID: 9454525
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
    Buysschaert M, Bobbioni E, Starkie M, Frith L.
    Diabet Med; 1999 Feb 01; 16(2):147-53. PubMed ID: 10229309
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S, Raskin P, Fonseca V, Graveline JF.
    N Engl J Med; 1998 Mar 26; 338(13):861-6. PubMed ID: 9516220
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.
    N Engl J Med; 1998 Mar 26; 338(13):867-72. PubMed ID: 9516221
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.
    Diabetes Care; 2002 Mar 26; 25(3):542-9. PubMed ID: 11874944
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.